Zobrazeno 1 - 10
of 1 086
pro vyhledávání: '"Glecaprevir"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Sheng-Shun Yang, Chia-Chi Wang, Jui-Ting Hu, Lein-Ray Mo, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Chia-Sheng Huang, Guei-Ying Chen, Chien-Neng Kao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Hsing-Tao Kuo, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wang-Long Chuang, Kuo-Chih Tseng, Chi-Yi Chen, Ming-Lung Yu
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 6, Pp 1199-1213 (2024)
Abstract Introduction Eight-week glecaprevir/pibrentasvir (GLE/PIB) is indicated for treatment-naïve (TN) patients with chronic hepatitis C (CHC), with or without compensated cirrhosis. Given that the Taiwanese government is committed to eliminating
Externí odkaz:
https://doaj.org/article/14215fa1ee784d7ab2393d1356d5db36
Publikováno v:
Journal of Virus Eradication, Vol 10, Iss 3, Pp 100388- (2024)
Background: To eliminate hepatitis C (HCV) infection as a public health concern by 2030, there is a need to develop comprehensive programs among key populations such as people who use drugs (PWUD). Two highly effective regimens are available for init
Externí odkaz:
https://doaj.org/article/004d50c9bbf04ef38ff6cd9d138ded74
Autor:
Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Hironori Ochi, Toshie Mashiba, Naohito Urawa, Hideki Fujii, Akeri Mitsuda, Masahiko Kondo, Chikara Ogawa, Yasushi Uchida, Ryoichi Narita, Hiroyuki Marusawa, Yoshihito Kubotsu, Tomomichi Matsushita, Masaya Shigeno, Hideo Yoshida, Katsuaki Tanaka, Eisuke Okamoto, Toyotaka Kasai, Toru Ishii, Kazuhiko Okada, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and aim In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non‐cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of
Externí odkaz:
https://doaj.org/article/0d9873a1fd55472ea90b8aee2ad5fcad
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 51, Iss 4, Pp 236-245 (2023)
Rationale: The first direct anti-viral agents (DAVA) for the treatment of adolescents with chronic hepatitis C virus (HCV) infection have been approved quite recently, i. e. in 2017 worldwide and in 2019 in Russia. Currently, only few adolescents are
Externí odkaz:
https://doaj.org/article/c1b217c8c89849198bbadb4081a002ea
Autor:
José Vera, André Gomes, Diana Póvoas, Diana Seixas, Fernando Maltez, Isabel Pedroto, Luís Maia, Margarida Mota, Maria João Vieira, Maria José Manata, Paula Ferreira, Sara Lino, Tiago Pereira Guedes, Vânia Barradas, Nuno Marques
Publikováno v:
Acta Médica Portuguesa (2024)
Introduction: Information about pan-genotypic treatments for hepatitis in Portugal is scarce. We aimed to evaluate the effectiveness and safety of glecaprevir plus pibrentasvir (GLE/PIB) treatment for hepatitis C virus (HCV) infection in real-world c
Externí odkaz:
https://doaj.org/article/c6949422f29c4c0cb3dfbb11673ce691
Autor:
Dwaipayan Mukherjee, Michelle Collins, Douglas E. Dylla, Jatinder Kaur, Dimitri Semizarov, Anthony Martinez, Brian Conway, Tipu Khan, Nael M. Mostafa
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 8, Pp 2057-2070 (2023)
Abstract Introduction An unsafe injection practice is one of the major contributors to new hepatitis C virus (HCV) infections; thus, people who inject drugs are a key population to prioritize to achieve HCV elimination. The introduction of highly eff
Externí odkaz:
https://doaj.org/article/e796bef6bd3e4e6ca9343e67f5fad543
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1849-1860 (2023)
Abstract Introduction The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatmen
Externí odkaz:
https://doaj.org/article/e225705152f14a45bfdfabaca715d207
Autor:
Ignacio García-Juárez, Carlos Alonzo-García, Alan G. Contreras, Fernanda Romero-Hernández, Maximiliano Servín-Rojas, Alfonso Fernández-Ramírez, Isaac Ruiz
Publikováno v:
Gaceta Médica de México, Vol 159, Iss 4 (2023)
Antecedentes: El tratamiento de la infección crónica por el virus de la hepatitis C (VHC) con antivirales de acción directa logra tasas de respuesta virológica sostenida superiores a 95 %. Sin embargo, el manejo del fracaso virológico sigue sien
Externí odkaz:
https://doaj.org/article/40c315056007438eb82ce6b338548325